B · Normal
[Betta Pharmaceuticals: Ensartinib Hydrochloride Capsules received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency] On September 20, Beida Pharmaceutical (300558.SZ) announced that the marketing authorization application for ensartinib hydrochloride capsules submitted by the company’s holding subsidiary The European Commission will make a final decision based on this positive opinion, and there is still uncertainty about whether the marketing authorization application can be approved. Ensartinib is a new generation ALK inhibitor that has been approved for marketing in China, the United States and Macau.
Comments